AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28719227 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20-40 mg/day)
Number of subjects: 70
Study 28719227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27467969 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge BNP
Number of subjects: 433
Study 27467969 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission BNP
Number of subjects: 433
Study 27467969 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage BNP reduction
Number of subjects: 433
Study 27467969 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of discharge BNP ≤319pg/mL and percentage BNP reduction ≥7.71%
Number of subjects: 433
Study 25200142 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5500
Study 25200142 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel with Aspirin followed by Clopidogrel
Number of subjects: 5500
Study 22094110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 187
Study 22094110 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 187
Study 20654757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-administered DMPA-SC
Number of subjects: 50
Study 20654757 — intervention group
Group type: COMPARATOR
Intervention: Clinic-administered DMPA-SC
Number of subjects: 50
Study 18316422 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention (CBT)
Number of subjects: 108
Study 18316422 — intervention group
Group type: COMPARATOR
Intervention: Stress management training (CBT)
Number of subjects: 108
Study 15834056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with exercises aiming at strengthening the stabilisers and decompressors of the shoulder
Number of subjects: 90
Study 15834056 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic subacromial decompression
Number of subjects: 90
Study 12434893 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (2.5 mmol/L serum Mg2+)
Number of subjects: 22
Study 12434893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12434893 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 22
Study 10651230 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride
Number of subjects: 40
Study 8936959 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human growth hormone (GH) 15 U/m2/week for 1 year (Groups (I)b, (II)a, (III)b)
Number of subjects: 77
Study 8936959 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 30 U/m2/week for 1 year (Group (I)a)
Number of subjects: 77
Study 8936959 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (both doses) for 1 year
Number of subjects: 77
Study 8936959 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (Group (III))
Number of subjects: 77
Study 1656741 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1, followed by 250 mg/day on days 2-5)
Number of subjects: 361
Study 1656741 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (500 mg twice daily for 10 days)
Number of subjects: 361
Study 1656741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 361
Study 6785476 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 48
Study 6785476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31734538 — intervention group
Group type: EXPERIMENTAL
Intervention: eVLU (internet-based education about VLU nursing care) for 6 weeks
Number of subjects: 468
Study 31734538 — intervention group
Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 468
Study 28463716 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + ICBT (n=33)
Number of subjects: 69
Study 28463716 — intervention group
Group type: COMPARATOR
Intervention: TAU (n=36)
Number of subjects: 69
Study 27112532 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI-087 (IV administration)
Number of subjects: 90
Study 27112532 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI-087 (SC administration)
Number of subjects: 90
Study 27112532 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI-087 (both IV and SC)
Number of subjects: 90
Study 27112532 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI-087 (with pre/posttreatment regimen)
Number of subjects: 90
Study 24332446 — intervention group
Group type: COMPARATOR
Intervention: High contrast PR-VEP
Number of subjects: 75
Study 24332446 — intervention group
Group type: COMPARATOR
Intervention: P100-N145 amplitude in high contrast PR-VEP
Number of subjects: 75
Study 24332446 — intervention group
Group type: COMPARATOR
Intervention: M-VEP (P1-N2 amplitudes)
Number of subjects: 75
Study 24332446 — intervention group
Group type: COMPARATOR
Intervention: Low contrast PR-VEP
Number of subjects: 75
Study 24332446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast and motion-onset stimuli
Number of subjects: 75
Study 22036871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 training sessions per week for 10 consecutive weeks)
Number of subjects: 54
Study 22036871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 54
Study 20092407 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary vaccination with 23-valent pneumococcal polysaccharide vaccine (PN23)
Number of subjects: 1008
Study 20092407 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23)
Number of subjects: 1008
Study 20092407 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary vaccination or revaccination with PN23
Number of subjects: 1008
Study 20092407 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with PN23
Number of subjects: 1008
Study 20092407 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 3 antibody levels
Number of subjects: 1008
Study 17906203 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil-based chemotherapy (CT)
Number of subjects: 785
Study 17906203 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 785
Study 16307705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% (Lumigan) eye drops
Number of subjects: 83
Study 16307705 — intervention group
Group type: COMPARATOR
Intervention: Filtration surgery (FS)
Number of subjects: 83
Study 11895063 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor and beta-blocker therapy
Number of subjects: 0
Study 11895063 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-ventricular end-diastolic volume (LVEDV)
Number of subjects: 0
Study 11895063 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma b-type natriuretic peptide (BNP)
Number of subjects: 0
Study 9798584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 40 mg or 80 mg
Number of subjects: 66
Study 9798584 — intervention group
Group type: COMPARATOR
Intervention: Gemeprost 1 mg
Number of subjects: 66
Study 9798584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 66
Study 9798584 — intervention group
Group type: COMPARATOR
Intervention: Gemeprost
Number of subjects: 66
Study 7865646 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 800 mg 5-ASA
Number of subjects: 21
Study 7865646 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral dose of 2400 mg/day for 56 days of 5-ASA
Number of subjects: 21
Study 7865646 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 21
Study 2645553 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5% once-daily treatment
Number of subjects: 71
Study 2645553 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5% twice-daily treatment
Number of subjects: 71
Study 31343520 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy availability (LEA) (18.9 ± 1.9 kcal·kg FFM·d)
Number of subjects: 7
Study 31343520 — intervention group
Group type: COMPARATOR
Intervention: Normal energy availability (NEA) (52.9 ± 5.0 kcal·kg FFM·d)
Number of subjects: 7
Study 29534902 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy (PMRT)
Number of subjects: 684
Study 29534902 — intervention group
Group type: COMPARATOR
Intervention: No postmastectomy radiation therapy (no-PMRT)
Number of subjects: 684
Study 29534902 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with no taxane
Number of subjects: 684
Study 29534902 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with no taxane (no-PMRT)
Number of subjects: 684
Study 28222779 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde perfusion with endoaortic clamp
Number of subjects: 0
Study 28222779 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic clamp
Number of subjects: 0
Study 26153884 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games and encouragement to play
Number of subjects: 270
Study 26153884 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 270
Study 23458257 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise for 8 weeks
Number of subjects: 17
Study 20672727 — intervention group
Group type: EXPERIMENTAL
Intervention: All Bond 3 (AB3) applied with various procedures (A, B, C)
Number of subjects: 0
Study 20672727 — intervention group
Group type: EXPERIMENTAL
Intervention: All Bond Self‐Etch (ABSE) applied with various procedures (A, B, C)
Number of subjects: 0
Study 18387444 — intervention group
Group type: EXPERIMENTAL
Intervention: VASP-guided group (additional bolus clopidogrel to decrease VASP index below 50%)
Number of subjects: 162
Study 18387444 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 162
Study 18387444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study 16631617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark soy sauce (DSS)
Number of subjects: 0
Study 16631617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15645932 — intervention group
Group type: EXPERIMENTAL
Intervention: meridol toothbrush with tapered filaments
Number of subjects: 87
Study 15645932 — intervention group
Group type: COMPARATOR
Intervention: ADA reference toothbrush
Number of subjects: 87
Study 10910026 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) performed on 5 consecutive days using an adsorber against immunoglobulins (Ig Therasorb, Baxter) with substitution of 0.5 g/kg of polyclonal immunoglobulin after the final session
Number of subjects: 9
Study 8852866 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 16
Study 8852866 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 16
Study 8852866 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 1353386 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 3 mg b.d. for 2 weeks
Number of subjects: 16
Study 1353386 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 16
Study 6584389 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 100 mg oxyphenbutazone daily
Number of subjects: 160
Study 6584389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 31403350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosurgery
Number of subjects: 93
Study 31403350 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 93
Study 31551204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin and thymosin
Number of subjects: 68
Study 31551204 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 68
Study 30011395 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfortified human milk (UHM)
Number of subjects: 281
Study 30011395 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula (PF)
Number of subjects: 281
Study 30011395 — intervention group
Group type: COMPARATOR
Intervention: Fortified human milk (FHM)
Number of subjects: 281
Study 26754447 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) intervention
Number of subjects: 50
Study 26754447 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 50
Study 24495849 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional context (emotional pictures)
Number of subjects: 0
Study 24495849 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral context (neutral pictures)
Number of subjects: 0
Study 24495849 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero context (blank screens)
Number of subjects: 0
Study 22764337 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifacet injection into the lumbar multifidus muscle with methylprednisolone
Number of subjects: 63
Study 22764337 — intervention group
Group type: EXPERIMENTAL
Intervention: Back education and gym ball exercise for 10 weeks
Number of subjects: 63
Study 22764337 — intervention group
Group type: COMPARATOR
Intervention: Back education and standard physiotherapy for 10 weeks
Number of subjects: 63
Study 20142346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg/mL, 20 mL given every third hour for 72 hours postoperatively.
Number of subjects: 40
Study 20142346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 40
Study 20142346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine group.
Number of subjects: 40
Study 16943848 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional baguette
Number of subjects: 9
Study 16943848 — intervention group
Group type: COMPARATOR
Intervention: Classic baguette
Number of subjects: 9
Study 15827103 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1 g/d)
Number of subjects: 1471
Study 15827103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1471
Study 12479545 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, approximately 8.5 mg/kg/day) given simultaneously for three days
Number of subjects: 204
Study 12479545 — intervention group
Group type: COMPARATOR
Intervention: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, sequentially administered)
Number of subjects: 204
Study 12479545 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, simultaneously)
Number of subjects: 204
Study 12479545 — intervention group
Group type: COMPARATOR
Intervention: Artesunate (4-5 mg/kg/day) and Mefloquine (25 mg/kg total, sequentially)
Number of subjects: 204
Study 12479545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 204
Study 12479545 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (simultaneous)
Number of subjects: 204
Study 12479545 — intervention group
Group type: COMPARATOR
Intervention: Group B (sequential)
Number of subjects: 204
Study 10531816 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention conducted in the clinic
Number of subjects: 0
Study 10531816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 9497660 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuhealth treatment (group A)
Number of subjects: 100
Study 9497660 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy (group B)
Number of subjects: 100
Study 9497660 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuhealth and occlusal splint therapy (group C)
Number of subjects: 100
Study 9497660 — intervention group
Group type: COMPARATOR
Intervention: Control (group D)
Number of subjects: 100
Study 2104736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg orally
Number of subjects: 15
Study 2104736 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin 0.8 mg spray
Number of subjects: 15
Study 281221 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus C.parvum
Number of subjects: 69
Study 281221 — intervention group
Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 69
Study 281221 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU plus C.parvum
Number of subjects: 69
Study 281221 — intervention group
Group type: COMPARATOR
Intervention: 5FU
Number of subjects: 69
Study 30453910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib and best available treatment (BAT)
Number of subjects: 160
Study 30453910 — intervention group
Group type: COMPARATOR
Intervention: Best available treatment (BAT)
Number of subjects: 160
Study 30453910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib and BAT
Number of subjects: 160
Study 30453910 — intervention group
Group type: COMPARATOR
Intervention: BAT
Number of subjects: 160
Study 28369188 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative self administration of intra‐venous analgesia by patients
Number of subjects: 0
Study 28369188 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 28369188 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal stratification and mediation analysis
Number of subjects: 0
Study 26195001 — intervention group
Group type: EXPERIMENTAL
Intervention: S. platensis supplementation and standard care
Number of subjects: 320
Study 26195001 — intervention group
Group type: COMPARATOR
Intervention: Standard care and local balanced diet without S. platensis
Number of subjects: 320
Study 23824463 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT, n = 11)
Number of subjects: 34
Study 23824463 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT, n = 11)
Number of subjects: 34
Study 23824463 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, n = 12)
Number of subjects: 34
Study 21161463 — intervention group
Group type: COMPARATOR
Intervention: OTW (over-the-wire balloon technique)
Number of subjects: 34
Study 21161463 — intervention group
Group type: EXPERIMENTAL
Intervention: PC (perfusion catheter)
Number of subjects: 34
Study 18498013 — intervention group
Group type: EXPERIMENTAL
Intervention: Close Monitoring (CM)
Number of subjects: 223
Study 18498013 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 223
Study 16192577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bec2 (2.5 mg)/BCG vaccine
Number of subjects: 515
Study 16192577 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 515
Study 16192577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bec2/BCG vaccine (among vaccinated patients)
Number of subjects: 515
Study 12194641 — intervention group
Group type: EXPERIMENTAL
Intervention: Airmax inhaler (100 micrograms BID)
Number of subjects: 25
Study 12194641 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler (100 micrograms BID)
Number of subjects: 25
Study 12194641 — intervention group
Group type: EXPERIMENTAL
Intervention: Airmax inhaler
Number of subjects: 25
Study 12194641 — intervention group
Group type: EXPERIMENTAL
Intervention: Airmax and Turbuhaler
Number of subjects: 25
Study 12194641 — intervention group
Group type: EXPERIMENTAL
Intervention: Airmax
Number of subjects: 25
Study 9468205 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal DCA
Number of subjects: 1000
Study 9468205 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 1000
Study 7607931 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.4 Gy of total body irradiation (TBI)
Number of subjects: 44
Study 7607931 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.2 Gy of total body irradiation (TBI)
Number of subjects: 44
Study 1724191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 0
Study 1724191 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 0
Study 1724191 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch (HES)
Number of subjects: 0
Study 364626 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg prednisolone once daily (single dose)
Number of subjects: 45
Study 364626 — intervention group
Group type: COMPARATOR
Intervention: 10 mg prednisolone four times a day (divided doses)
Number of subjects: 45
Study 31446990 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine and cisplatin (OVP)
Number of subjects: 140
Study 31446990 — intervention group
Group type: COMPARATOR
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 140
Study 27941383 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 111
Study 27941383 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood
Number of subjects: 111
Study 27140800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib powder for oral suspension
Number of subjects: 144
Study 27140800 — intervention group
Group type: COMPARATOR
Intervention: Commercial tablet formulation of lapatinib
Number of subjects: 144
Study 23916965 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy (CBT) with therapist support for 6 weeks using the MoodGYM program.
Number of subjects: 106
Study 21810677 — intervention group
Group type: EXPERIMENTAL
Intervention: MVAC chemotherapy (methotrexate, vinblastine, doxorubicin, and cisplatin) for three cycles
Number of subjects: 521
Study 21810677 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group for p53-positive patients)
Number of subjects: 521
Study 19803020 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chlorpheniramine plus chloroquine (6 mg + 12 mg/day for 7 days in children ≤ 5 years; 8 mg + 18 mg/day for 7 days in those >5 years) plus chloroquine 10 mg/kg daily for 3 days
Number of subjects: 99
Study 19803020 — intervention group
Group type: COMPARATOR
Intervention: Higher dose chlorpheniramine plus chloroquine (50% higher dose) plus chloroquine 10 mg/kg daily for 3 days
Number of subjects: 99
Study 17268417 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group supplemented daily with 6 mg lutein combined with vitamins and minerals.
Number of subjects: 25
Study 17268417 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=10).
Number of subjects: 25
Study 15115982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (34 degrees C)
Number of subjects: 144